Voriconazole and fluconazole susceptibility of Candida isolates

被引：21

作者：

Pelletier, R ^{[1
]}

Loranger, L

Marcotte, H

De Carolis, E

机构：

[1] Ctr Hosp Univ Quebec, Hotel Dieu, Microbiol Lab, Quebec City, PQ, Canada

[2] Pfizer Canada, Antiinfect Res & Dev Grp, Kirkland, PQ, Canada

来源：

JOURNAL OF MEDICAL MICROBIOLOGY | 2002年 / 51卷 / 06期

关键词：

D O I：

10.1099/0022-1317-51-6-479

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

An adapted NCCLS M27-A method was used to evaluate the activity of voriconazole (VRC) and fluconazole (FLC) against 295 Candida isolates collected from 189 patients (including isolates from deep sites). Isolates included 186 C. albicans, 54 C. glabrata, 27 C. tropicalis, 14 C. parapsilosis, 6 C. krusei, 6 C. lusitaniae, 1 C. lypolytica and 1 C. sake. Forty-two isolates had reduced susceptibility to FLC (MIC >8 mg/L); 83.3% of these had VRC MICs less than or equal to2 mg/L (9 of 11 C. albicans, 18 of 19 C. glabrata, 6 of 6 C. krusei, 2 of 2 C. lusitaniae and 0 of 4 C. tropicalis), including 60% of isolates collected from deep-seated infections. These results suggested that in the era of azole resistance, VRC has a promising antifungal activity for serious infections with Candida spp., including most species with low susceptibility to FLC and uncommonly isolated species.

引用

页码：479 / 483

页数：5

共 27 条

[1] Quality control limits for broth microdilution susceptibility tests of ten antifungal agents [J].

Barry, AL ;

Pfaller, MA ;

Brown, SD ;

Espinel-Ingroff, A ;

Ghannoum, MA ;

Knapp, C ;

Rennie, RP ;

Rex, JH ;

Rinaldi, MG .

JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (09) :3457-3459

[2] In vitro studies of two triazole antifungal agents (Voriconazole [UK-109,496] and fluconazole) against Candida species [J].

Barry, AL ;

Brown, SD .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1948-1949

[3] Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain [J].

Cuenca-Estrella, M ;

Díaz-Guerra, TM ;

Mellado, E ;

Monzón, A ;

Rodríguez-Tudela, JL .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1999, 18 (06) :432-435

[4] International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections [J].

Edwards, JE ;

Bodey, GP ;

Bowden, RA ;

Buchner, T ;

dePauw, BE ;

Filler, SG ;

Ghannoum, MA ;

Glauser, M ;

Herbrecht, R ;

Kauffman, CA ;

Kohno, S ;

Martino, P ;

Meunier, F ;

Mori, T ;

Pfaller, MA ;

Rex, JH ;

Rogers, TR ;

Rubin, RH ;

Solomkin, J ;

Viscoli, C ;

Walsh, TJ ;

White, M .

CLINICAL INFECTIOUS DISEASES, 1997, 25 (01) :43-59

[5] Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model [J].

Ghannoum, MA ;

Okogbule-Wonodi, I ;

Bhat, N ;

Sanati, H .

JOURNAL OF CHEMOTHERAPY, 1999, 11 (01) :34-39

[6] Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? [J].

Goldman, M ;

Cloud, GA ;

Smedema, M ;

LeMonte, A ;

Connolly, P ;

McKinsey, DS ;

Kauffman, CA ;

Moskovitz, B ;

Wheat, LJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (06) :1585-1587

[7]

Hegener P, 1998, AIDS, V12, P2227

[8] Effects of voriconazole on Candida glabrata in vitro [J].

Koul, A ;

Vitullo, J ;

Reyes, G ;

Ghannoum, M .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (01) :109-112

[9] The changing face of nosocomial candidemia: Epidemiology, resistance, and drug therapy [J].

Lewis, RE ;

Klepser, ME .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1999, 56 (06) :525-533

[10] In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. [J].

Marco, F ;

Pfaller, MA ;

Messer, S ;

Jones, RN .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) :161-163

← 1 2 3 →